Multiple sclerosis (Houndmills, Basingstoke, England) · 2020
Expanding spectrum of opportunistic infections associated with dimethyl fumarate.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Tiffany, Croteau David, Brinker Allen, Jones David E, Lee Paul R, Kortepeter Cindy M
Аннотация
BACKGROUND: Only progressive multifocal leukoencephalopathy (PML) is currently described in the dimethyl fumarate (DMF) prescribing information.
OBJECTIVES: To describe opportunistic infections (OIs), other than PML, reported in association with DMF.
METHODS: The FDA Adverse Event Reporting System (FAERS) and medical literature were searched.
RESULTS: We retrieved 34 cases of serious OIs with a causal association with DMF, including 11 central nervous system (CNS) infections and 23 extra-CNS infections. Six OIs occurred with normal circulating absolute lymphocyte counts. The median latency from DMF initiation was 13 months and was variable.
CONCLUSION: DMF is associated with the development of OIs that require invasive diagnostic and/or therapeutic procedures. Patients should be monitored for OIs when treated with DMF regardless of circulating absolute lymphocyte counts.
OBJECTIVES: To describe opportunistic infections (OIs), other than PML, reported in association with DMF.
METHODS: The FDA Adverse Event Reporting System (FAERS) and medical literature were searched.
RESULTS: We retrieved 34 cases of serious OIs with a causal association with DMF, including 11 central nervous system (CNS) infections and 23 extra-CNS infections. Six OIs occurred with normal circulating absolute lymphocyte counts. The median latency from DMF initiation was 13 months and was variable.
CONCLUSION: DMF is associated with the development of OIs that require invasive diagnostic and/or therapeutic procedures. Patients should be monitored for OIs when treated with DMF regardless of circulating absolute lymphocyte counts.